NCT03480568View on ClinicalTrials.gov

Alirocumab in Patients on a Stable Dialysis Regimen

PHASE3UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

August 31, 2020

Study Completion Date

December 31, 2020

Conditions
HemodialysisPeritoneal DialysisHypercholesterolemiaAtherosclerotic Disease
Interventions
DRUG

Alirocumab 150 MG/ML [Praluent]

Cholesterol-lowering therapy

Trial Locations (1)

75226

RECRUITING

Baylor Soltero CV Research, Dallas

Sponsors
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Baylor Research Institute

OTHER

NCT03480568 - Alirocumab in Patients on a Stable Dialysis Regimen | Biotech Hunter | Biotech Hunter